Onco Actu du 6 avril 2016

	1. Biologie
JAX Researchers Reveal Genomic Culprit, Treatment Strategy for Some Deadly Cancers [JAX] A research team led by Jackson Laboratory (JAX) President and CEO Edison Liu, M.D., has found a molecular fingerprint of some of the most deadly cancers of women: a genomic configuration described as a tandem duplicator phenotype (TDP) that is significantly enriched in triple-negative breast cancer, serous ovarian cancer and endometrial carcinomas, and that responds to a specific chemotherapy.
	3. Prévention
Six ways to reduce your risk of bowel cancer [Cancer Research UK] Making small changes to our day-to-day lives can make a big difference to the risk of developing bowel cancer. Read on to find out how, and share our graphic on social media to help spread the word this month.
	4.12 Biopsies liquides
Merck receive CE Mark approval for new liquid biopsy test for colorectal cancer [Pharmafile] The test will now be made widely accessible for patients in Europe, Asia and Australia.
New Liquid Biopsy RAS Testing for Metastatic Colorectal Cancer Patients now Available for Clinical Practices [sysmex inostics] The OncoBEAM® RAS CRC assay has been shown to have similar performance to conventional tissue-based testing1-3 and can be used to determine which patients would benefit from anti-EGFR therapies, such as Erbitux, as demonstrated by recent data.
	5.2 Pharma
What new GSK patent policy means for the developing world [Nature News & Comment] Analysts welcome focus on cancer drugs for poorest countries but caution that more work needs to be done.
	5.2.1 Pharma - Partenariats
MedImmune, Regeneron Launch Cancer Collaboration [GEN] Regeneron Pharmaceuticals said today it will use MedImmune’s pyrrolobenzodiazepine (PBD)-based "warhead" and linker technology to produce antibody–drug conjugates (ADCs) as potential cancer treatments.
Old guard meets new as Pfizer and Merck start PDL1-TKI combo trial for kidney cancer [FierceBiotech] Pfizer will bring its marketed kidney cancer drug Inlyta to the table while Darmstadt-based Merck will introduce its experimental anti-PD-L1 drug avelumab to the mix as a first-line treatment for patients with advanced renal cell carcinoma (RCC), a type of kidney cancer.
	5.2.2 Pharma - Fusions & Acquisitions
Pfizer to call off $160 billion merger with Allergan [Pharmafile] US pharma giant Pfizer Inc has decided to terminate the $160 billion merger with Botox-maker Allergan Plc according to reports, ending the biggest pharma deal as the US lawmakers take to enforcing stricter rules for corporations trying to dodge taxes.
	5.4 Traitements - Economie
Cancer drug prices skyrocketing on high costs of developing 'molecular targeted drugs' [The Mainichi] In Japan, the prices of newly-approved cancer drugs have been rising sharply since the 2000s, with the development and introduction of "molecular targeted drugs" that are designed to attack specific cancer cells.
Making the Price Right: Ideas To Change Drug Costs Gain Momentum [Xconomy] Lo and Weinstock want to convene a conference this fall to flesh out the loan idea. Whether their brainchild actually grows into a loan program or not, elements of it are common to many of the creative ideas now in play, so the conversation should be welcome. For many, the question isn’t if changes are coming, it’s when.
	6. Lutte contre les cancers
Choir singing may boost immunity in people affected by cancer [NHS Choices] Despite the optimistic media headlines – changes in levels of immune proteins alone are no evidence that singing could "beat cancer".
Putting patients first to ease the effects of complex illnesses [NICE] Professor David Haslam, Chair of NICE, talks about the challenges of tackling multimorbidity.
	6.4 Médico-éco
Patients Miss Out On Savings When Doctors Fail To Talk About Costs [NPR] The researchers analyzed transcripts of almost 2,000 physician-patient conversations regarding breast cancer, rheumatoid arthritis and depression treatment. They identified instances in which patients suggested the cost of care might be difficult for them to bear and assessed how doctors responded.
	6.6 Publications
ORCID: what, why, how? [BioMed Central blog] If you’re a researcher or work in a research organization, the chances are that over the past couple of years you’ve started to hear about ORCID. Maybe you’re one of the over 2million people who have already signed up for an ORCID iD, or you know colleagues who have.
Cancer researcher earns 9th retraction, for image duplication [Retraction Watch] Alfredo Fusco, a researcher in Italy who has been under criminal investigation for scientific misconduct, has earned his ninth retraction. Retraction number nine, by The Journal of Clinical Investigation, is for duplicating data from another publication.
Amid Public Feuds, A Venerated Medical Journal Finds Itself Under Attack [Pro Publica] A widely derided editorial, a controversial series of articles and delayed corrections have prompted critics to question the direction of the New England Journal of Medicine.
	6.7.2 Applis
Why every clinical trial should have an app for participants [STAT] These tools can make it easier for clinical trial sponsors to improve engagement, whether it’s making participation easier by reducing the need for trips to a clinic or providing reminders for taking medicines in the right dose at the right time.